Immunologically defined prognostic subgroups as predictors of response to BCG immunotherapy.
Fifty-two stage I and II patients with nonsmall cell lung cancer were randomized after resection to no further therapy, BCG, or BCG plus allogeneic tumor cells. Patients have been observed for 16-65 months (mean 39.5). When the two immunotherapy arms were combined and plotted against controls, trend analysis suggested (P = 0.088) an increase in disease-free interval  (DFI) only for stage I patients. The one-way mixed lymphocyte culture (MLC) values were depressed in some patients prior to any immune stimulation. Immunotherapy significantly benefited DFI among patients with a depressed MLC.
D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008214:Lymphocytes / Q000276:immunology; D009163:Mycobacterium bovis / Q000276:immunology; D009367:Neoplasm Staging; D011379:Prognosis